Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|December 25, 2024
CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot studyChezi Ganzel, Avraham Frisch, Ofir Wolach, et al.
Acta Haematologica|April 17, 2025
Epiglottitis in Patients Treated for Acute Leukemia - Case Series and Systematic Review of the LiteratureAdi Sherban, Avraham Frisch, Alon Rozental, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 12, 2019
Baseline Chest Computed Tomography for Early Diagnosis of Invasive Pulmonary Aspergillosis in Hemato-oncological Patients: A Prospective Cohort StudyRoni Bitterman, Emilia Hardak, Marina Raines, et al.
Leukemia Research|July 1, 2022
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center studyAvraham Frisch, Shlomzion Aumann, Tsila Zuckerman, et al.
Annals of Hematology|September 13, 2019
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control studyTamar Berger, Uri Rozovski, Yakir Moshe, et al.
Annals of Hematology|June 22, 2022
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysisOfir Wolach, Avraham Frisch, Liat Shargian, et al.
Annals of Hematology|June 23, 2022
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysisShai Shimony, Jonathan Canaani, Eitan Kugler, et al.
European Journal of Haematology|September 19, 2020
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remissionYishai Ofran, Ronit Leiba, Avraham Frisch, et al.
European Journal of Haematology|May 31, 2023
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemiaJonathan Canaani, Avraham Frisch, Daniel A Pollyea, et al.
American Journal of Hematology|April 9, 2021
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practiceArie Apel, Yakir Moshe, Yishai Ofran, et al.
Pageof 3